Bethyl Laboratories
Rabbit anti-BRD8 IHC Antibody Affinity Purified
Primary
Catalog #IHC-00020
TargetBRD8
HostRabbit
ClonalityPolyclonal
ReactivityHuman
ApplicationIHC
Image 1 of 1
local_shipping
Order within 3 hours and 31 minutes for shipment by today
Product Description
BRD8 (bromodomain-containing 8) has been identified as a thyroid hormone receptor coactivator as well as a GTPase activating protein (GAP) for Arf6 that regulates clathrin-dependent vesicle trafficking. BRD8 has also been identified as a gene upregulated during formation of the neointima layer of blood vessels and named smooth muscle activating protein 2 (SMAP2).
Specifications
Clonality
Polyclonal
Host
Rabbit
Immunogen
Between 250 and 300 of isoform 2
Isotype
IgG
Reactivity
Human
Format
Whole IgG
Conjugate Type
Unconjugated
Purity
Antigen Affinity Purified
Concentration
250 µg/ml
Target Identity
TargetBRD8
Antigen Species
Human
Gene ID10902
Gene Symbol
BRD8
Gene Name
bromodomain containing 8
Uniprot IDQ9H0E9
Protein Name
Bromodomain-containing protein 8
Product Information
Applications
IHC
Buffer
Tris-buffered Saline containing 0.1% BSA and 0.09% Sodium Azide
Storage Conditions
2 - 8 °C
Physical State
Liquid
Shelf Life
1 year from date of receipt
Country of Origin
USA
Production & Epitope
Antibody was affinity purified using an epitope specific to BRD2 immobilized on solid support.
The epitope recognized by IHC-00020 maps to a region between residue 200 and 250 of human Bromodomain containing 8 using the numbering given in TrEMBL entry Q969M9 (GeneID 10902).
Applications
Epitope exposure is recommended.
Immunohistochemistry (IHC)1:100 - 1:500
Documents
Safety Data SheetPDF · IHC-00020Open
Product DatasheetPDF · IHC-00020 · Lot 1 (current lot)Open
Product DatasheetPDF · IHC-00020 · Lot 1 (current lot)Open
Citations / Publications
Services
Antibody Conjugation
Antibody and conjugate formats developed together, built to your specification.
Request CustomizationCustom Monoclonal Antibody Discovery Services
Full custom monoclonal development, from immunization through validation.
Explore Monoclonal DevelopmentVHH Discovery
Single-domain antibodies for structurally difficult targets a conventional monoclonal can't reach.
Explore VHH DiscoveryResources
1